Prestige Consumer Healthcare Inc. $PBH Holdings Trimmed by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC cut its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 5.6% during the 3rd quarter, Holdings Channel.com reports. The fund owned 509,668 shares of the company’s stock after selling 30,225 shares during the quarter. Prestige Consumer Healthcare accounts for about 1.7% of Rice Hall James & Associates LLC’s portfolio, making the stock its 12th biggest position. Rice Hall James & Associates LLC’s holdings in Prestige Consumer Healthcare were worth $31,803,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Intech Investment Management LLC lifted its stake in Prestige Consumer Healthcare by 18.9% during the first quarter. Intech Investment Management LLC now owns 27,307 shares of the company’s stock valued at $2,348,000 after purchasing an additional 4,343 shares during the last quarter. AXQ Capital LP bought a new position in shares of Prestige Consumer Healthcare in the second quarter valued at $694,000. Assenagon Asset Management S.A. acquired a new stake in shares of Prestige Consumer Healthcare during the 3rd quarter valued at $1,890,000. Voya Investment Management LLC boosted its stake in shares of Prestige Consumer Healthcare by 19.5% during the 1st quarter. Voya Investment Management LLC now owns 41,717 shares of the company’s stock worth $3,586,000 after acquiring an additional 6,798 shares in the last quarter. Finally, Keystone Wealth Services LLC acquired a new position in shares of Prestige Consumer Healthcare in the 2nd quarter worth $315,000. 99.95% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Prestige Consumer Healthcare

In related news, VP Jeffrey Zerillo sold 719 shares of the stock in a transaction on Friday, November 28th. The stock was sold at an average price of $60.00, for a total transaction of $43,140.00. Following the completion of the sale, the vice president directly owned 42,329 shares in the company, valued at approximately $2,539,740. This trade represents a 1.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.40% of the company’s stock.

Prestige Consumer Healthcare Price Performance

Shares of PBH opened at $62.87 on Friday. The business’s 50-day moving average is $60.79 and its 200-day moving average is $67.41. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.70 and a quick ratio of 2.51. The company has a market capitalization of $3.02 billion, a price-to-earnings ratio of 15.60, a P/E/G ratio of 1.96 and a beta of 0.39. Prestige Consumer Healthcare Inc. has a fifty-two week low of $57.25 and a fifty-two week high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, November 6th. The company reported $1.07 EPS for the quarter, beating analysts’ consensus estimates of $0.97 by $0.10. Prestige Consumer Healthcare had a net margin of 18.09% and a return on equity of 12.43%. The firm had revenue of $274.11 million for the quarter, compared to the consensus estimate of $257.14 million. During the same period in the previous year, the firm posted $1.09 earnings per share. The firm’s revenue was down 3.4% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. Equities research analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently commented on PBH. Zacks Research raised Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, November 10th. Canaccord Genuity Group reduced their price objective on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Sidoti upgraded shares of Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 target price for the company in a report on Wednesday, September 24th. Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Wednesday, October 8th. Finally, Oppenheimer reduced their price target on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a research report on Tuesday, October 21st. Four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, Prestige Consumer Healthcare has an average rating of “Moderate Buy” and a consensus price target of $85.33.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).